Gemini Priming Attenuates Inflammation in Human Peripheral Blood Mononuclear Cells
Revelation Biosciences, Inc. (NASDAQ: REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is ...
Physician's Weekly1d
Haploidentical Transplants with Low-Dose ATG and PTCy Improve Outcomes in Older Patients
The following is a summary of “Improved survival in older patients with myeloid malignancies undergoing haploidentical ...
ALZFORUM14d
Sex Differences in Blood of Alzheimer’s and Parkinson’s Patients
Sex Delta by Cell Type. In men with Alzheimer’s (top left), B cells (red boxes) were fewer (blue), while NK cells (blue boxes ...
CURE2d
Darzalex Plus Revlimid Improves Outcomes in Newly Diagnosed Myeloma
Darzalex and Revlimid maintenance resulted in superior outcomes versus Revlimid alone following autologous stem cell ...
AHA/ASA Journals8d
Myeloid Fatty Acid Metabolism Activates Neighboring Hematopoietic Stem Cells to Promote Heart Failure With Preserved Ejection Fraction
BACKGROUND: Despite the high morbidity and mortality of heart failure with preserved ejection fraction (HFpEF), treatment ...
Monte Rosa Therapeutics announces results from MRT-6160, MRT-2359 programs
Monte Rosa announced clinical results from its MRT-6160 Phase 1, single ascending dose / multiple ascending dose study. Details about the ...
Everyday Health13d
What Is T-Cell Lymphoma?
T-cell lymphoma is a rare cancer that affects the lymphatic system. Learn about the types, signs, symptoms, treatments, and ...
BioPharma Dive3d
Orca Bio to seek approval of T cell transplant after positive trial data
Results showed Orca’s treatment, a purified mix of donor-derived T cells and stem cells, was safer than standard transplant ...
A brief guide to vitamin and mineral supplements – when too much of a good thing can become toxic
Although your body will store excess vitamin A, some research shows having more than 1.5mg a day over many years may weaken ...
Corvus Pharmaceuticals Announces Presentation of Additional Data from the Phase 1/1b Clinical Trial of Soquelitinib for Patients with T Cell Lymphoma
The data from the Phase 1/1b clinical trial of soquelitinib in patients with T cell lymphoma continues to demonstrate strong indications of anti-tumor activity in a significant number of patients,” ...